As the world commemorates World Malaria Day on April 25, Bond Chemical Industries Ltd., a pharmaceutical company, has restated its commitment in the fight to eradicate malaria in Nigeria and sub-Saharan Africa.
The Managing Director of the company, Mr Remi Omotosho, in a statement on Wednesday said malaria has continued to be a significant global health challenge, affecting millions of lives in Nigeria and across African regions.
The theme of the 2024 World Malaria Day is “Accelerating the fight against malaria for a more equitable world”.
According to the World Health Organiaztion, malaria is an acute febrile illness caused by Plasmodium parasites, which are spread to people through the bites of infected female Anopheles mosquitoes.
WHO report also indicates that infants and young children continue to suffer the greatest mortality; in 2022, an estimated four out of five malaria-related deaths in the African Region were among children under five years of age.
Omotosho said the company’s quest to eradicate malaria in the country has engendered the manufacturing of Temexcin Plus, a brand of Dihydroartemisinin and Piperaquine Phosphate, an innovative antimalarial product.
ALSO READ: WHO to begin vaccination against HPV May 27
He said Temexcin Plus has been developed through years of rigorous research and has clinically proven to be safe and efficacious.
Omotosho said: “We at Bond Chemical Industries Limited wish to reaffirm our commitment to eradicating malaria by providing accessible and effective solutions to communities.
“Achieving the vision of a malaria-free world, everyone has the right to quality, timely, and affordable services to prevent, detect, and treat malaria, yet this is not a reality for all.
ALSO READ: USAID-IHP supports FG to improve service delivery in PHCs
“Our drug offers a safe defence against malaria with unparalleled precision while minimizing the risk of side effects and relapse commonly associated with traditional antimalarial medications.
“We are dedicated to ensuring widespread access to Temexcin Plus, particularly in underserved communities where malaria poses the greatest threat.
NAN
